Dr. Hutchinson is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
27151 Green Hills LN
Laguna Hills, CA 92653Phone+1 424-444-7399Fax+1 424-253-0814
Education & Training
- University of California (Irvine)Residency, Family Medicine, 1981 - 1985
- The University of Toledo College of MedicineClass of 1981
Certifications & Licensure
- CA State Medical License 1982 - 2026
- American Board of Family Medicine Family Medicine
Publications & Presentations
PubMed
- 75 citationsDepression and anxiety: effect on the migraine-obesity relationship.Gretchen E. Tietjen, B. Lee Peterlin, Jan Lewis Brandes, Faizan Hafeez, Susan Hutchinson
Headache. 2007-06-01 - 40 citationsDiscontinuation of Acute Prescription Medication for Migraine: Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study.Richard B. Lipton, Susan Hutchinson, Jessica Ailani, Michael L. Reed, Kristina M. Fanning
Headache. 2019-11-01 - 86 citationsChildhood maltreatment and migraine (part III). Association with comorbid pain conditions.Gretchen E. Tietjen, Jan Lewis Brandes, B. Lee Peterlin, Arnolda Eloff, Rima M. Dafer
Headache. 2010-01-01
Lectures
- It's Time to Redefine Expectations Around the Acute Treatment of Migraine
- Achieving Success In Primary Care: Practical Approaches To Challenging & Complicated Patients - Hilton Head, ScDestination CME, Hilton Head, South Carolina - 9/12/2013
- Achieving Success in Primary Care: Practical Approaches to Challenging & Complicated PatientsPrimary Care Network, Inc., Coeur D Alene, Idaho - 9/5/2013
- Join now to see all
Press Mentions
- Birx Notes Harm of Virus FatigueAugust 18th, 2020
- Lilly's OVERCOME Study Reveals Less Than 30 Percent of People Living with Migraine Take Recommended Prescription MedicationsJune 16th, 2020
- Long‐Term Safety Evaluation of Ubrogepant for the Acute Treatment of Migraine: Phase 3, Randomized, 52‐Week Extension TrialJanuary 8th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: